Posted by Michael Wonder on 01 May 2025
Up to 1,000 women a year could benefit from new at-home treatment for endometriosis
1 May 2025 - Our final draft guidance recommends linzagolix (Yselty, Theramex) with hormonal add-back therapy for adults of reproductive age and who've already tried other medical or surgical treatments for their endometriosis.
We used a faster evaluation process to assess this treatment by comparing its costs with similar treatments and standard care options. Our committee found that Linzagolix offers similar benefits at a comparable cost, giving patients more treatment choices.
The medicine was approved by the UK regulator (MHRA) on 14 March, 2025. Our final guidance on linzagolix is due to be published on 25 June, after which the NHS in England must make the treatment available within 90 days.
